Clinical Trials
13
Active:8
Completed:1
Trial Phases
2 Phases
Phase 1:5
Phase 3:4
Drug Approvals
20
CANADA:6
EMA:4
CIMA_AEMPS:4
Drug Approvals
Vyxeos liposomal (previously known as Vyxeos)
- Authorization Status
- Authorised
- Approval Date
- Aug 23, 2018
EMA
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (55.6%)Phase 3
4 (44.4%)No trials found
News
Zymeworks Receives FDA Clearance for ZW251, Novel Glypican-3 Targeted ADC for Hepatocellular Carcinoma
The FDA has cleared Zymeworks' investigational new drug application for ZW251, a first-in-class antibody-drug conjugate targeting glypican-3 for hepatocellular carcinoma treatment.